Hematology NewsMayo experts outline Waldenström macroglobulinemia managementNovember 21, 2017Indolent Lymphoma
Hematology NewsFDA approves obinutuzumab for follicular lymphomaNovember 17, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsVCR regimen showed efficacy in mantle cell and indolent lymphomasOctober 6, 2017Mantle Cell LymphomaLymphoma & Plasma Cell DisordersIndolent LymphomaFollicular Lymphoma
Hematology NewsFDA grants Priority Review to Gazyva for follicular lymphomaAugust 29, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsCopanlisib makes inroads against relapsed/refractory follicular lymphomaJuly 11, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsIbrutinib/buparlisib looks good for relapsed mantle cell lymphomaJune 27, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsPembrolizumab + rituximab boost response rates in relapsed follicular lymphomaJune 26, 2017Indolent LymphomaImmunotherapyLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsBendamustine plus rituximab may have edge for treating indolent NHL, MCLJune 22, 2017Mantle Cell LymphomaIndolent LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsLenalidomide-rituximab induces high CR rate in untreated follicular lymphomaJune 21, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsGALEN safe and effective in relapsed and refractory follicular lymphomaJune 20, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsSubcutaneous rituximab safe, effective for follicular lymphomaMay 9, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsIbrutinib monotherapy data in previously treated MZL is availableMay 2, 2017Indolent LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsWaldenström macroglobulinemia panel advises on IgM paraproteinemic neuropathiesApril 19, 2017Indolent LymphomaLeukemia, Myelodysplasia, Transplantation
Hematology NewsObinutuzumab vs. rituximab weighed as follicular lymphoma therapyApril 18, 2017Indolent LymphomaLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsPhase III trial: VZV protects auto-HCT patientsFebruary 25, 2017Multiple MyelomaT Cell LymphomasMantle Cell LymphomaIndolent LymphomaAggressive LymphomasPreventive CareLymphoma & Plasma Cell Disorders
